- Global Pharma News & Resources

Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants

Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced the issuance of European patent No. 3008186, which claims methods to create gene-edited plants by the transient delivery of sequence-specific nucleases, including CRISPR/Cas9. This patent, granted by the European Patent Office, is owned by Cellectis and licensed exclusively to Calyxt.

“Conventionally, gene editing is performed by delivering DNA to cells,” says Dr. Dan Voytas, Calyxt’s Chief Science Officer and University of Minnesota Professor. “The DNA encodes a nuclease, such as CRISPR/Cas9, which makes the gene edit. The problem with conventional gene editing is that DNA can integrate randomly into the genome, creating off-target effects. For example, genes can be disrupted by the incoming DNA that you didn’t intend to disrupt. Calyxt has accomplished a precise method of gene editing that creates plants with the desired traits.”

Although Calyxt elected TALEN® to develop its food products, the company is constantly testing new gene editing technologies and inventing new methods and approaches to edit plant genes. Calyxt’s intellectual property portfolio is also strengthened by having licensed from Cellectis two patents of a family claiming the uses of chimeric nucleases, such as TALEN® and CRISPR/Cas9, for gene editing in any type of cells.

“Over the last eight years, Calyxt has rapidly grown, building a versatile lineup of gene editing technologies and a product pipeline that delivers healthier food products to consumers,” explains Jim Blome, Calyxt’s Chief Executive Officer. “We are excited by the continued expansion of our patent portfolio to include new tools to produce crops that produce healthier food while reducing input costs.”

Claim 1 of EP 3008186

A method for targeted genetic modification of a plant genome without inserting exogenous genetic material into the genome comprising:

(i) providing a plant cell that comprises an endogenous gene to be modified;
(ii) providing a Cas9 endonuclease protein targeted to the endogenous gene; and
(iii) transfecting the plant cell with said Cas9 endonuclease protein using biolistic or protoplast transformation, such that the Cas9 endonuclease introduces one or more double stranded DNA breaks (DSB) in the genome, to produce a plant cell or cells having a detectable targeted genomic modification without the presence of any exogenous Cas9 genetic material in the plant genome.

About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, Minn., and is listed on the Nasdaq market (ticker: CLXT).

For further information please visit our website:
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis S.A.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K, and Cellectis’ Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2017 along with other Calyxt and Cellectis subsequent filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.

View source version on

Editor Details

Last Updated: 17-Dec-2018